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Abstract
Background: Topical haemostatic agents are used to help achieve haemostasis during surgery when standard surgical
techniques are insufficient. The objective of this study was to confirm the safety profile of an equine collagen patch coated
with human fibrinogen and human thrombin with particular focus on the occurrence of thromboembolic events (TEEs),
major bleeding and immunological events.
Methods: This was a non-interventional, multicentre, prospective, surveillance study in which a collagen fleece-bound
fibrin sealant was prescribed in accordance with its marketing authorisation. The decision to use the sealant was based
solely on current surgical practice. All patients that received the sealant and provided informed consent were included.
TEEs (any coagula-based occlusion in a vessel or the heart identified by symptomatic clinical signs and/or verified by
paraclinical examination), major bleeding (any bleeding that required intervention), and immunological events
(hypersensitivity including anaphylaxis) that occurred during surgery, post-operative hospital stay or 6 months of follow-
up were reported as adverse events. The primary endpoint was the proportion of patients experiencing a confirmed TEE.
Results: A total of 3098 patients were recruited at 227 centres in 12 European countries. The most frequent types of
surgery were hepatic (33%), gastrointestinal (16%) and urological (14%) and the main indication for surgery was for
primary (35%) or secondary (20%) malignancy. Forty-six patients (1.5%, 95% CI 1.1–2.0%) had at least one TEE during
the study. The most commonly reported TEEs were pulmonary embolism or post-procedural pulmonary embolism (n =
18) and deep vein thrombosis (n = 9). There were 64 major bleedings in 62 patients and 9 immunological events in 8
patients.
Conclusion: Collagen fleece-bound fibrin sealant does not appear to be associated with an increased risk of TEEs, major
bleeding or immunological events in patients undergoing surgery.
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Rapid and effective control of bleeding during surgery
reduces blood loss and can help decrease post-operative
morbidity and mortality. Ligation, stapling, clipping and
electrocautery are all widely used techniques to prevent
bleeding. Over the past 20 years, a wide variety of topical
haemostatic agents such as fleeces of different origin (col-
lagen-based, e.g. Avitene®; gelatine-based, e.g. Surgifoam®,
Gelfoam®; regenerated oxidised cellulose-based, e.g. Sur-
gicel®, Curacel®), liquid fibrin sealants (e.g. Tisseel®, Tissu-
col®, Evicel®, Beriplast®), albumin and glutaraldehyde
bioglue (BioGlue®) and synthetic glues (e.g. CoSeal®) have
increasingly been used in a range of surgical procedures to
help achieve haemostasis when standard surgical tech-
niques are insufficient [1-3]. The use of these agents has a
beneficial effect on surgical outcomes, including
improved haemostasis, fewer complications and reduced
duration of post-operative hospital stay [1,2].
TachoSil® is a sterile, absorbable, haemostatic agent that
consists of an equine collagen patch coated on one side
with human fibrinogen and human thrombin. Unlike
other fibrin sealants that require preparation before use,
TachoSil is a ready-to-use fixed combination that is acti-
vated by moisture on application, providing adherence to
the resection surface and haemostasis. The adhesive
strength of TachoSil has been shown to be significantly
higher than that of liquid fibrin glue [4] and the effect of
the fibrinogen and thrombin together with the mechani-
cal support of the collagen patch provides a physiologi-
cally extensible and pliable liquid and air tight seal [5].
TachoSil and its predecessor products, TachoComb® and
TachoComb H, have been used in a variety of surgical set-
tings since being introduced in the early 1990s. TachoSil
is indicated for supportive treatment in surgery for
improvement of haemostasis, to promote tissue sealing,
and for suture support in vascular surgery where standard
techniques are insufficient.
Clinical studies have shown that TachoSil is effective in
achieving haemostasis after kidney or liver resection [6,7],
as well as preventing air leakage after lung surgery [8,9]
and reducing lymphatic fluid production from the medi-
astinum [10]. TachoSil has also been shown to be safe and
well tolerated, with occurrence of adverse events similar in
TachoSil and non-TachoSil treated patients in controlled
trials [6-10].
The objective of this study was to confirm the established
safety profile of TachoSil with particular focus on the
occurrence of thromboembolic events (TEEs), major
bleeding and immunological events. The possible role of
drug interactions in TEEs and major bleeding was also
investigated.
Methods
This international, multicentre, prospective, surveillance
study was of a non-interventional design, meaning that
TachoSil was prescribed in accordance with the terms of
its marketing authorisation. The decision to use TachoSil
was made by the surgeon solely on the basis of current
clinical practice. No additional diagnostic or monitoring
procedures were applied.
Relevant Ethics Committees approved the protocol, and
the trial was conducted in accordance with the Declara-
tion of Helsinki, Good Pharmacoepidemiology Practice,
the Data Protection Directive and any additional local reg-
ulations. A Data Monitoring Committee (DMC), which
comprised of three surgeons (KG, DM, FM) not involved
in recruiting patients to the study, was established before
the protocol was finalised to regularly review the data. All
patients provided written informed consent in accordance
with local regulations, allowing the collection of personal
data, direct data access and data processing. Consent
could be provided either before or after surgery but all
were obtained before data were entered into the study
database. All patients that received TachoSil and provided
informed consent were included in this study.
Reportable adverse events (AEs) were any TEE (a coagula-
based occlusion in a vessel or the heart identified by
symptomatic clinical signs and verified by paraclinical
examination, e.g. ultrasound, magnetic resonance or com-
puted tomography scan, or identified by paraclinical
examination only [no routine paraclinical examination]),
major bleeding (any bleeding that required intervention),
or immunological event (hypersensitivity including ana-
phylaxis) that occurred during surgery, post-operative
hospital stay or 6 months of follow-up. Follow-up at 6
months was done either by personal contact (telephone
or visit) or by review of patients' medical records by the
participating physician. Reportable AEs were coded by
system organ class using MedDRA terminology (version
10.1). AE severity was defined as mild (transient symp-
toms, no interference with daily activities), moderate
(marked symptoms, moderate interference with daily
activities) or severe (considerable interference with daily
activities). Serious AEs were defined as those that resulted
in death, were life-threatening, required overnight inpa-
tient hospitalisation or prolongation of existing hospital-
isation, resulted in persistent or significant disability/
incapacity, involved congenital anomaly or birth defect,
or that required intervention to prevent any of the previ-
ously listed. Causality between TachoSil and reportable
AEs were assessed by the participating physician and
defined as probable (good reason and sufficient docu-
mentation to assume a causal relationship), possible
(causal relationship conceivable), unlikely or not related.Page 2 of 8
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bolic or major bleeding event was possibly or probably
caused by a drug interaction between TachoSil and a con-
comitant medication then this was documented.
Demographic characteristics, known risk factors for TEEs,
bleeding and immunological events, ECG data, and surgi-
cal indication were documented for all patients. During
surgery, the type and volume of blood products used was
documented, as was the use of TachoSil. Use of anticoag-
ulant therapy was assessed before, during and after sur-
gery. Concomitant medication use was also recorded
before, during and after surgery, as well as during the 6-
month follow-up.
Statistical analysis
The primary endpoint was the proportion of patients
(with 95% confidence intervals [CIs]) experiencing a con-
firmed TEE. All proportions were based on the number of
patients exposed at a given timepoint with no adjustment
for multiplicity or missing values. The number and per-
centage of patients experiencing a serious TEE or a TEE at
least possibly related to TachoSil were also summarised.
Secondary endpoints included the proportion of patients
experiencing an immunological event, the proportion of
patients experiencing a major bleeding requiring interven-
tional treatment, and drug interactions with TachoSil
resulting in a TEE or major bleeding. Immunological
events and major bleedings were summarised in a similar
manner to TEEs.
A review of the literature available before the study began
suggested that the incidence of TEEs for surgical proce-
dures without the use of TachoSil was 10–15%. On this
basis, an observed incidence rate of 10% could be esti-
mated with a precision (2-sided 95% CI) of ± 1.1% and an
observed incidence rate of 15% could be estimated with a
precision (2-sided 95% CI) of ± 1.3% with a sample size
of 3000 patients.
During the study, all written consents were checked and
collected data were verified against the source for approx-
imately 10% of patients (patients with an ID number on
their case report form with end digit 2, not revealed to
sites until after the study) and for all reportable serious
AEs.
Results
Patient and surgical characteristics
Between June 2005 and June 2007, 3098 patients received
TachoSil while undergoing surgery and provided written
informed consent to the use of their data. Patient data
were collected from 227 surgical departments or clinics in
12 European countries (Germany, 1548 patients; France,
n = 461; Spain, n = 343; Greece, n = 161; Austria, n = 146;
the Netherlands, n = 119; Sweden, n = 98; Belgium, n =
82; Latvia, n = 76; UK, n = 41; Norway, n = 15; and Den-
mark, n = 8). Almost all patient consents were obtained
after surgery. No patients withdrew their consent during 6
months of follow-up. A total of 179 patients discontinued
from the study early (death, n = 156; lost to follow-up, n
= 20; other reasons, n = 3).
Over half of the patients were male (56%), most were
Caucasian (98%) and their mean ± SD age was 61 ± 14
years. The most frequent types of surgery were hepatic
(33%), gastrointestinal (16%) and urological (14%). The
main indication for surgery was for primary (35%) or sec-
ondary (20%) malignancy. Ten percent of patients
received surgery for benign neoplastic disease. Demo-
graphic characteristics and surgical variables are summa-
rised in Table 1.
Of 2752 patients who had an ECG before surgery, 17.3%
(n = 477, 15.4% of total study population) had abnormal
results. Forty-three percent of patients (n = 1327) received
anti-coagulant prophylaxis before surgery. Of these, 95%
had their coagulation status tested, and of those tested
11% (n = 139) had abnormal coagulation status. During
surgery, or between surgery and hospital discharge, 80%
of patients (n = 2491) received anti-coagulant prophy-
laxis, with 20% (n = 440) of the 90% tested having abnor-
mal coagulation status.
A total of 892 patients (29%) received blood transfusion.
Erythrocyte concentrate was the most frequently given
blood product (n = 736), followed by fresh frozen plasma
(n = 362), whole blood (n = 84) and platelets (n = 65).
The median volume of blood products given was 3 units
(range 1–83 units) (data available for 873 patients). The
median area of TachoSil used was 45.6 cm2 (range 0.3–
616.3 cm2), the size of one standard patch, based on the
amount used during surgery without any correction for
overlap of multiple patches.
The majority of patients (91%) had at least one baseline
risk factor for a TEE (Table 2). A risk factor for bleeding
was reported for 8.2% of patients (bleeding or bleeding
tendency, 4.6%; abnormal pre-operative coagulation test,
4.5%) and 15.3% of patients had a risk factor for an
immunological event (known allergy, 13.4%; any auto-
immune disease, 2.6%).
The most frequently used classes of concomitant medica-
tions were heparins (79% of patients), proton pump
inhibitors (60%), anilides (e.g. paracetamol) (43%), ben-
zodiazepine derivatives (33%), opioid anaesthetics
(32%), cephalosporins and related substances (31%),Page 3 of 8
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ics (28%).
Safety
A total of 124 AEs were reported; 51 TEEs in 46 patients,
64 major bleedings in 62 patients and 9 immunological
events in 8 patients. Thirteen events were considered to be
at least possibly related to TachoSil (3 TEEs, 8 major
bleedings and 2 immunological events) by study surgeons
or other physicians (Table 3).
Thromboembolic events (TEEs)
A total of 46 patients (1.5%, 95% CI 1.1–2.0%) had at
least one TEE at any time during the study (primary end-
point).
The most commonly reported TEEs were pulmonary
embolism or post-procedural pulmonary embolism (18
patients), deep vein thrombosis (n = 9), phlebitis (n = 3),
embolism (not otherwise specified) (n = 2), subclavian
vein thrombosis (n = 2), portal vein thrombosis (n = 2),
thrombosis (not otherwise specified) (n = 2) and myocar-
dial infarction (n = 2). TEEs occurred on the day of surgery
in 2 patients, and between the date of surgery and hospital
discharge in 23 patients, with the remainder occurring
during follow-up. TEEs by time of occurrence (up to one
month post-surgery) are shown in Figure 1.
Twelve patients had mild TEEs (12 events), while moder-
ate and severe TEEs each occurred in 17 patients (19 and
20 events, respectively). Forty-one patients had a TEE that
was considered serious (46 events).
Table 1: Baseline demographic and surgical characteristics
All patients (n = 3098) Patients with TEE (n = 46) Patients with major bleeding 
(n = 62)
Patients with immunological 
event (n = 8)
Age (years), mean ± SD 60.7 ± 14.0 63.0 ± 10.0 58.6 ± 16.5 59.5 ± 11.8
Gender (female/male), % 43.7/56.3 28.3/71.7 32.3/67.7 37.5/62.5
BMI (kg/m2), mean ± SD 26.6 ± 4.9 27.2 ± 4.4 26.3 ± 6.1 26.0 ± 5.4
Type of surgery, n (%):
Hepatic 1007 (32.5%) 22 (47.8%) 16 (25.8%) 3 (37.5%)
Gastrointestinal 500 (16.1%) 7 (15.2%) 13 (21.0%) 2 (25.0%)
Urological 422 (13.6%) 2 (4.3%) 6 (9.7%) 1 (12.5%)
Vascular 227 (7.3%) 5 (10.9%) 3 (4.8%) 0
Pulmonary 224 (7.2%) 4 (8.7%) 6 (9.7%) 1 (12.5%)
Cardiac 173 (5.6%) 0 5 (8.1%) 1 (12.5%)
Gynaecological 130 (4.2%) 0 1 (1.6%) 0
Neurosurgical 83 (2.7%) 2 (4.3%) 1 (1.6%) 0
Other 424 (13.7%) 4 (8.7%) 10 (16.1%) 0
Indication for surgery, n (%):
Primary malignancy 1074 (34.7%) 20 (43.5%) 17 (27.4%) 3 (37.5%)
Secondary malignancy 619 (20.0%) 12 (26.1%) 7 (11.3%) 3 (37.5%)
Benign neoplastic disease 306 (9.9%) 2 (4.3%) 7 (11.3%) 0
Other 1098 (35.4%) 12 (26.1%) 31 (50.0%) 2 (25.0%)
Surgery, acute/elective, % 10.2/89.8 10.9/89.1 24.2/75.8 12.5/87.5
Duration of surgery (hours), 
mean ± SD
3.2 ± 1.8 4.4 ± 2.4 3.7 ± 2.4 4.4 ± 2.8
Patients receiving blood 
transfusion, n (%)
892 (28.8%) 14 (30.4%) 31 (50.0%) 2 (25.0%)
Number of transfusion units 
given, mean ± SD
5.2 ± 7.3 9.5 ± 12.1 10.0 ± 15.9 3.5 ± 2.1
Area of TachoSil used (cm2), 
mean ± SD
53.7 ± 40.7 60.1 ± 41.4 51.7 ± 36.3 55.1 ± 40.8Page 4 of 8
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sibly related to TachoSil by the study surgeon or other
physician. Two of these were considered to be serious; one
patient had phlebitis in the left leg 11 days after surgery,
which was of moderate severity, while another patient
had severe, post-procedural pulmonary embolism one
week after surgery. Both patients recovered without seque-
lae. The third TEE considered possibly related to TachoSil
was portal vein thrombosis of mild severity with onset
two days after surgery. None of the seven TEEs leading to
death were considered related to TachoSil.
Major bleeding
Sixty-two patients (2.0%, 95% CI: 1.5–2.6%) had at least
one major bleeding (64 events). Most major bleedings
occurred on the day of surgery (n = 24) or between surgery
and hospital discharge (n = 28) (Figure 1).
A total of 55 patients had 57 serious major bleeding
events, with 8 events in 7 patients considered at least pos-
sibly related to TachoSil. These included post-procedural
haemorrhage in 3 patients, one on the day of surgery, one
the day after surgery and one 4 days after surgery. One
post-procedural haemorrhage was severe and 2 were mod-
erate in severity. The other events considered at least pos-
sibly related to TachoSil were severe haemothorax, severe
haemorrhage, moderately severe splenic haemorrhage,
and moderately severe haematoma, all of which occurred
on the day of surgery. In addition, drug ineffective was
reported as an AE in the patient with moderately severe
splenic haemorrhage. All 4 patients recovered, although
the patient with haematoma died later from sepsis. None
of the 8 major bleeding events leading to death was con-
sidered related to TachoSil.
Immunological events
Eight patients (0.3%) experienced at least one immuno-
logical event. The most common immunological events
were rash or rash pruritis, which occurred in 3 patients.
No immunological events were reported during surgery,
while 5 occurred between surgery and discharge. One
immunological event was deemed serious but not related
Table 2: Patients with known risk factors at baseline for thromboembolic events
Thromboembolic risk factor: All patients (n = 3098) Patients with TEE (n = 46) Patients with no TEE (n = 3052) P-value*
Any thromboembolic risk factor 2813 (90.8%) 42 (91.3%) 2771 (90.8%) >0.99
Cardiovascular (CV) risk factor: 2135 (68.9%) 31 (67.4%) 2104 (68.9%) 0.87
Personal/family history of TEEs 64 (2.1%) 2 (4.3%) 62 (2.0%) 0.25
≥ 1 other CV risk factor 2122 (68.5%) 31 (67.4%) 2091 (68.5%) 0.87
Chronic obstructive pulmonary disease 365 (11.8%) 6 (13.0%) 359 (11.8%) 0.82
Cancer 1597 (51.5%) 30 (65.2%) 1567 (51.3%) 0.07
Metabolic/endocrinological risk factor 797 (25.7%) 15 (32.6%) 782 (25.6%) 0.31
Other thromboembolic risk factor 270 (8.7%) 6 (13.0%) 264 (8.7%) 0.29
Abnormal pre-operative ECG 477 (15.4%) 10 (21.7%) 467 (15.3%) 0.22
* From Fishers Exact test of 2 × 2 tables comparing for each risk factor to which extent the risk factor was predictive of the occurrence of TEEs
Table 3: Occurrence of thromboembolic, major bleeding and immunological events
All Mild Moderate Severe Serious TachoSil-related*
Thromboembolic events 51 12 19 20 46 3
Major bleeding 64 4 27 33 57 8
Immunological events 9 6 3 0 1 2
*Considered at least possibly-related to TachoSil by the participating physician (probable = good reason and sufficient documentation to assume a 
causal relationship; possible = causal relationship conceivable). Mild = transient symptoms, no interference with daily activities; moderate = marked 
symptoms, moderate interference with daily activities; severe = considerable interference with daily activities; serious = resulted in death, life-
threatening, required overnight inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/
incapacity, involved congenital anomaly or birth defect, or that required intervention to prevent any of the previous occurrence of any of the 
previously listed.Page 5 of 8
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patient had 2 immunological events considered to be at
least possibly related to TachoSil (pyrexia and eosi-
nophilia).
Previous exposure to TachoSil among patients was
unknown. Seven patients were reported to be participat-
ing or had previously participated in another clinical trial
or non-interventional study with TachoSil, while 2
patients received TachoSil on two occasions during this
study. None of these patients experienced an immunolog-
ical event.
Drug interactions
No drug interactions with TachoSil were suspected by the
participating physician as the cause of a TEE or major
bleeding. Over 38 000 concomitant medications were
recorded, coded and grouped to ATC code level 4, with an
average of 12.3 concomitant drugs per patient. To identify
possible drug interactions, odds ratios (OR) were calcu-
lated post-hoc based on drug classes and number of
exposed patients with and without events. With Hochberg
correction for multiple testing, the only significant OR
was for natural opium alkaloids and TEEs (OR 3.7, p =
0.022). However, this was considered to be attributable to
the underlying conditions of patients receiving opioids,
rather than any interaction with TachoSil.
Discussion
This prospective, non-interventional European surveil-
lance study, conducted in a real-world clinical setting, sug-
gests that patients undergoing surgery who receive
TachoSil are not at increased risk of TEEs, major bleeding
or immunological events.
The study cohort was representative of patients treated
with TachoSil in clinical practice. The most common type
of surgery was hepatic, which is the most documented use
of TachoSil and was the most frequently observed type of
surgery in a previous surveillance study [11]. Almost all
patients (94%) received TachoSil for haemostasis, with
the other 6% receiving TachoSil for sealing purposes, such
as the prevention of air leakage.
TachoSil did not appear to be associated with an increased
risk of TEEs, with only three patients experiencing a TEE
that was considered by the reporting physician to be at
least possibly related to TachoSil. Possible causal relation-
ships between TachoSil and AEs were not reviewed by the
DMC. The overall reported incidence of TEEs in this study
(1.5%) is much lower than the expected 10–15%, which
was based on a review of the available literature. However,
this expected incidence may have been an over-estimate.
Meta-analyses of thromboprophylaxis in major surgery
suggest that the incidence of TEEs in patients receiving
Occurrence of thromboembolic, major bleeding and immunological events by time from surgeryFigure 1
Occurrence of thromboembolic, major bleeding and immunological events by time from surgery.Page 6 of 8
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around 5% [12-14]. Moreover, the incidence of clinically
detected TEEs is only 1–2%, given that the majority of
TEEs are clinically silent and only detected using a system-
atic approach. Thus, the reported 1.5% occurrence in this
study is consistent with previous observations, given that
the majority of patients (79%) received heparins during
or after surgery and that no systematic testing for TEEs was
done.
Under-reporting of reportable AEs is a concern in large-
scale non-interventional studies, since more events may
go unnoticed and the recording of events in medical
records may be less rigorously implemented compared
with a controlled trial setting. In addition, events that are
reported may be missed when data are transferred to the
study due to inadequate staff training and monitoring and
less intensive source data verification. In particular, the
follow-up of patients transferred to other hospitals after
surgery can be challenging and may lead to under-report-
ing of AEs. This was a particular concern in this study for
those countries where 6-month follow-up could not be
done through direct contact with patients, but only
through review of medical records.
However, source data verification of 10% of patients did
not suggest that a significant number of AEs were missed,
with a similar occurrence of events reported for patients
with different end digits of their patient number (Chi-
squared test, p = 0.8). In addition, incidences of AEs were
similar in patients followed-up by personal contact and
those who only had their medical records reviewed. These
findings suggest that under-reporting was not a significant
problem in this study.
The reported 2% incidence of major bleeding is in line
with our experience. However, the protocol defined major
bleeding as requiring interventional treatment. This defi-
nition may have been imprecise, especially given the het-
erogeneity of the cohort and range of surgical procedures.
For instance, it is possible that major bleeding was consid-
ered in subjective terms, only being reported if in excess of
what was expected. Transfusions were given to 29% of
patients; however, transfusions are not only given because
of a major bleeding, but may be given because of disease-
related anaemia (e.g. in patients with cancer) or as a rou-
tine preventative measure for fluid and haemodynamic
reposition, despite increasing evidence that this common
clinical practice may be associated with increased morbid-
ity and mortality [15].
Peri-operative anti-coagulant prophylaxis was reported in
80% of patients. The lack of anti-coagulant use in the
remaining 20% may be largely attributable to under-
reporting of therapy. However, it is also possible that a
trend towards earlier post-operative mobilisation of
patients following surgery, at least in certain countries,
may have reduced the use of prophylactic anti-coagulant
therapy.
Another potential limitation with the design of this study
was the issue of patient consent. All patients had to pro-
vide written informed consent, which could be obtained
either before or after surgery. However, obtaining consent
before surgery would have meant it was necessary to
obtain consent from large numbers of patients who did
not subsequently receive TachoSil, a considerable burden
on the time and resources of participating centres. More
importantly, obtaining consent before surgery carried the
risk that surgeons may have been encouraged to use
TachoSil in situations where they otherwise may not have
done so. To avoid this, Ethics Committees in certain coun-
tries (Austria, Denmark and Germany) specified that con-
sent must be obtained after surgery, in order to prove that
surgeons' were not influenced in their decision to use
TachoSil. However, obtaining consent after surgery meant
that patients who died during surgery could not be
included and AEs in these patients would not be reported,
potentially resulting in selection bias and an underestima-
tion of mortality and AEs. Illustrating this dilemma, six
local Ethics Committees in Spain specified consent had to
be obtained before surgery, while one stated that consent
must be obtained post-surgery. In practice, almost all con-
sents were obtained after surgery. However, since almost
all reported TEEs occurred in the post-surgical phase, and
since only 10% of TEEs and major bleedings had fatal
consequences, the order of magnitude of any possible
selection bias was likely to have been small.
Occurrence of immunological events was low (<1%), sug-
gesting there is no immunological risk with TachoSil.
Hypersensitivity or allergic reactions may occur in rare
cases in patients treated with fibrin sealant, especially if
the preparation is applied repeatedly. Of particular con-
cern, cross-reaction of antibodies against bovine
thrombin and factor V with human factor V has been
widely reported after exposure to topical bovine thrombin
[16-18]. The risk of immunological reaction to TachoSil is
minimal since the fibrinogen and thrombin are of human
origin (no bovine material), while the equine collagen
patch is free of immunogenic epitopes and is unlikely to
induce an immune response [19]. It was impossible to
ascertain whether patients had previous exposure to
TachoSil. Seven patients reported that they had previously
participated or were participating in another clinical study
of TachoSil, although it was not possible to confirm
whether these patients were actually treated with
TachoSil. Two patients received TachoSil on two occa-
sions during this study. None of these patients experi-
enced an immunological event.Page 7 of 8
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human plasma, and the equine collagen fleece is derived
from horse tendons, the potential for virus infection has
to be considered. Standard measures to prevent infections
resulting from the use of medicinal products prepared
from human blood or plasma include selection of donors,
and screening of individual donations and plasma pools
for specific markers of infection. In addition, the manu-
facture of TachoSil includes several processing steps (e.g.
pasteurisation, precipitation and adsorption, polymerase-
chain-reaction, sterilisation by gamma irradiation)
intended to reduce the risk of viral transmission. No viral
infections have been reported as AEs in clinical studies of
TachoSil and no proven virus transmission has been
detected up to the present since its approval in Europe.
There was no indication of any drug interactions between
TachoSil and concomitant medications, as assessed by
participating physicians and a post-hoc multiplicity cor-
rected analysis of ORs of number of patients with and
without events for each concomitant drug class.
Conclusion
In conclusion, TachoSil does not appear to be associated
with an increased risk of TEEs, major bleeding or immu-
nological events in patients undergoing surgery. In addi-
tion, there is no evidence of any interaction between
TachoSil and other medications resulting in an increased
risk of TEEs or major bleeding. These findings support
previous experience that the use of TachoSil in a variety of
surgical procedures is safe and well tolerated.
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